These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 22929563

  • 1. Effect of matrix metalloproteinase and their inhibitors on atrial myocardial structural remodeling.
    Wang W, Zhang HT, Yang XL.
    J Cardiovasc Med (Hagerstown); 2013 Apr; 14(4):265-9. PubMed ID: 22929563
    [Abstract] [Full Text] [Related]

  • 2. [Role of matrix metalloproteinase and tissue inhibitor of metalloproteinase in atrial structural remodeling in patients with atrial fibrillation].
    Wang W, Wu PS, Yang XL.
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 May; 30(5):1160-2. PubMed ID: 20501421
    [Abstract] [Full Text] [Related]

  • 3. [Changes in gelatinases expression and activity in human atria during atrial fibrillation].
    Ke D, Xu CX, Zhang JC, Chen L, Lin YZ, Lin LF, Hu XZ.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Feb; 33(2):137-42. PubMed ID: 15924808
    [Abstract] [Full Text] [Related]

  • 4. [Comparison of right atrial matrix metalloproteinase expression between patients with unstable angina and myocardial infarction].
    Wang W, Wu PS, Yang XL.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2010 May; 38(5):411-4. PubMed ID: 20654099
    [Abstract] [Full Text] [Related]

  • 5. [Clinical on molecular basis of atrial fibrosis in patients with atrial fibrillation investigation].
    Ke D, Xu CX, Lin YZ, Zhang JC, Chen L, Lin LF, Hu XZ.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 May; 33(5):459-63. PubMed ID: 15932710
    [Abstract] [Full Text] [Related]

  • 6. [Effects of matrix metalloproteinase-9 and tissue inhibitor-1 of metalloproteinase expression on atrial structural remodeling during chronic atrial fibrillation].
    Zhu H, Zhang W, Guo CH, Zhang G, Zhang WD, Zhong M, Yang GR, Ge ZM, Zhang Y.
    Zhonghua Yi Xue Za Zhi; 2005 Jan 05; 85(1):45-8. PubMed ID: 15808077
    [Abstract] [Full Text] [Related]

  • 7. Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation.
    Anné W, Willems R, Roskams T, Sergeant P, Herijgers P, Holemans P, Ector H, Heidbüchel H.
    Cardiovasc Res; 2005 Sep 01; 67(4):655-66. PubMed ID: 15913581
    [Abstract] [Full Text] [Related]

  • 8. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation.
    Mukherjee R, Herron AR, Lowry AS, Stroud RE, Stroud MR, Wharton JM, Ikonomidis JS, Crumbley AJ, Spinale FG, Gold MR.
    Am J Cardiol; 2006 Feb 15; 97(4):532-7. PubMed ID: 16461051
    [Abstract] [Full Text] [Related]

  • 9. [Effects of doxycycline on the expression of matrix metalloproteinase and tissue inhibitor of MMP in myocardium after acute myocardial infarction: an animal experiment with rats].
    Zhang P, Yang YJ, Chen X, Ruan YM, Zhou YW, Tian Y, Chen ZJ.
    Zhonghua Yi Xue Za Zhi; 2004 Aug 02; 84(15):1288-93. PubMed ID: 15387968
    [Abstract] [Full Text] [Related]

  • 10. TGF-β1 and TIMP-4 regulate atrial fibrosis in atrial fibrillation secondary to rheumatic heart disease.
    Sun Y, Huang ZY, Wang ZH, Li CP, Meng XL, Zhang YJ, Su F, Ma N.
    Mol Cell Biochem; 2015 Aug 02; 406(1-2):131-8. PubMed ID: 25971370
    [Abstract] [Full Text] [Related]

  • 11. [Comparison of doxycycline, losartan, and their combination on the expression of matrix metalloproteinase, tissue inhibitor of matrix metalloproteinase, and collagen remodeling in the noninfarcted myocardium after acute myocardial infarction in rats].
    Zhang P, Yang YJ, Chen X, Ruan YM, Zhou YW, Tian Y, Chen ZJ.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Feb 02; 27(1):53-61. PubMed ID: 15782494
    [Abstract] [Full Text] [Related]

  • 12. Role of metalloproteinases and tissue inhibitors of metalloproteinases during cardiopulmonary bypass in rats.
    Guenzinger R, Lahm H, Wottke M, Lange R.
    ASAIO J; 2012 Feb 02; 58(3):204-11. PubMed ID: 22395114
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Expression and significance of matrix metalloproteinase-1,9, tissue inhibitor of metalloproteinase-4 and extracellular matrix metalloproteinase inducer in the myocardium of congestive heart failure in patients with rheumatic heart diseases].
    Zhao Y, Zhou X, Liao X, Yang Z.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Aug 02; 34(8):790-5. PubMed ID: 19734590
    [Abstract] [Full Text] [Related]

  • 16. Angiotensin II receptor type 1 is upregulated in atrial tissue of patients with rheumatic valvular disease with atrial fibrillation.
    Cong H, Li X, Ma L, Jiang H, Mao Y, Xu M.
    J Thorac Cardiovasc Surg; 2010 Aug 02; 140(2):298-304. PubMed ID: 20080265
    [Abstract] [Full Text] [Related]

  • 17. Extracellular matrix remodeling attenuated after experimental postinfarct left ventricular aneurysm repair.
    Hsu CP, Huang CY, Wang JS, Sun PC, Shih CC.
    Ann Thorac Surg; 2008 Oct 02; 86(4):1243-9. PubMed ID: 18805169
    [Abstract] [Full Text] [Related]

  • 18. Atorvastatin reduces myocardial fibrosis in a rat model with post-myocardial infarction heart failure by increasing the matrix metalloproteinase-2/tissue matrix metalloproteinase inhibitor-2 ratio.
    An Z, Yang G, He YQ, Dong N, Ge LL, Li SM, Zhang WQ.
    Chin Med J (Engl); 2013 Oct 02; 126(11):2149-56. PubMed ID: 23769575
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.